XML 206 R162.htm IDEA: XBRL DOCUMENT v3.22.4

Liabilities related to business combinations and to non-controlling interests - Additional Information (Details) € in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable		€ 779	€ 714	€ 605	€ 800
Commitments relating to contingent consideration in connection with business combinations		604	689	1,043
Bayer contingent consideration
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Payment to sale of business period	10 years
Milestone payment period	2021
Fair value of contingent consideration payable		€ 26	59	104
Increase in fair value of liability		1.00%
Bayer contingent consideration | Top of range
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Potentiel payments related to percentage of sales of alemtuzumab | $	$ 1,250,000,000
MSD contingent consideration (European vaccines business)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable		€ 204	269	312
Increase in fair value of liability		1.00%
Fair value of contingent consideration payable		€ 204	269	312	385
Shire contingent consideration
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Increase in fair value of liability		13.00%
Amunix
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Increase in fair value of liability		1.00%
Fair value of contingent consideration payable		€ 165	€ 0	€ 0	€ 0

X

- Definition

The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2021-01-01
-Paragraph B67
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Commitments Relating To Contingent Consideration In Connection With Business Combinations

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Fair value of the contingent consideration payable

+ References

No definition available.

+ Details

Name:	sny_FairValueOfContingentConsiderationPayable
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Milestone payment term.

+ References

No definition available.

+ Details

Name:	sny_MilestonePaymentTerm
Namespace Prefix:	sny_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Payment to sale of business period.

+ References

No definition available.

+ Details

Name:	sny_PaymentToSaleOfBusinessPeriod
Namespace Prefix:	sny_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage increase in fair value liabilities.

+ References

No definition available.

+ Details

Name:	sny_PercentageIncreaseInFairValueLiabilities
Namespace Prefix:	sny_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Potentiel payments related to percentage of sales.

+ References

No definition available.

+ Details

Name:	sny_PotentialPaymentsRelatedToPercentageOfSales
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_BayerScheringPharmaAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_ShireHumanGeneticTherapiesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_AmunixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: